Keng has been invited to speak at the Skin@Bath Skin & Synovium Network Symposium in December 2026. His talk will focus on our dual-domain, semi-dissolving and hydrogel-forming microneedle technologies.
The talk is scheduled for the second day of the symposium, 11 December 2026.
Over the last two years, our lab has developed three pharmaceutical technologies. At first glance, they might seem unrelated. But they all share a rather unexpected origin.
In this video podcast, Keng speaks with Dr Manveer Sandhu about how it all began with a single research challenge: developing a long-acting microneedle formulation.
The work required laboratory equipment that wasn’t readily available, so we decided to build our own. That decision set in motion a series of developments that eventually led to the three technologies we have today.
Watch the conversation below to discover how one research challenge led to three different pharmaceutical technologies.
Many thanks to Manveer for inviting us to share our story on his Signal over Noise podcast series.
Want to learn more? Visit our Publications section to explore the scientific papers behind these technologies.
Liang YM, Azizi J, Ng KW, Goh CF. Transdermal delivery and formulation design of opioids: Where are we now and where are we heading? J Control Release. 2026;394:114894. https://doi.org/10.1016/j.jconrel.2026.114894
This has been another excellent transnational collaboration with Dr Choon Fu Goh and colleagues. In this paper, we take a deep dive into a seemingly simple question with a deceptively complex answer: why is it so difficult to deliver opioid drugs across the skin?
Transdermal delivery offers clear advantages for opioid therapy, including more stable drug levels and improved patient convenience compared to oral or injectable routes. However, only a small number of opioids, such as fentanyl and buprenorphine, have been successfully developed into marketable patches. The main limitation is the skin itself. As a barrier, it is highly effective, and drugs require a very specific balance of properties, including molecular size, lipophilicity, and potency, to cross it. Many widely used opioids, including morphine, fall outside this narrow window.
In the review, we examine the main strategies that have been explored to address this challenge, including chemical permeation enhancers, formulation approaches, and physical methods. A consistent theme is that success in controlled laboratory settings does not always translate into clinical use. Improving permeation alone is not sufficient if the system cannot deliver clinically relevant doses reliably in practice. It increasingly appears that formulation strategies relying on passive diffusion across intact skin are unlikely to succeed. Looking ahead, active skin penetration strategies are likely to lead progress by enabling more consistent drug delivery while reducing dosing burden.
I thank my co-authors for their contributions to this work, and I hope the review will serve as a useful resource for the research community.
We are delighted to welcome Anas Al-Masri to our research team as a PhD student.
Anas holds a BSc in Pharmacy from Syrian Private University and an MSc in Transfusion and Transplantation Sciences from the University of Bristol. He has a particular interest in innovative drug delivery systems and translational pharmaceutical technologies.
His PhD research will focus on developing long-acting ULTRA microneedles for the delivery of biologic drugs, particularly GLP-1 agonists. He will work closely with his supervisory team: Professor Katarina Novakovic, Dr Wing Man Lau and Dr Tarek Abdelghany.
Welcome to the team, Anas! We look forward to working with you.
Abdelghany TM, Vo N, Vukajlovic D, Smith E, Wong JZ, Jackson E, Hilkens CMU, Lau WM, Ng KW, Novakovic K. Engineering and in vitro evaluation of semi-dissolving, hydrogel-forming polymeric microneedles for sustained-release drug delivery. Int J Pharm. 2025:125932. https://doi.org/10.1016/j.ijpharm.2025.125932
In our latest paper, we describe a microneedle formulation that utilises two polymeric domains: a soluble one and an insoluble one. The insoluble domain is chemically crosslinked and traps the soluble polymer, along with the drug, within it. This combination creates a microneedle array patch that can release a drug for over 2 months.
It can contain a significantly larger dose than microneedles where the drug is contained within the microneedle tips only (e.g., detachable microneedles). The drug reservoir in the backplate makes this possible to support extended release. It uses one-pot synthesis, a mild hydroalcoholic solvent system and mild temperatures to aid manufacturability and drug stability.
For the first time, we were able to see, on video, how the microneedles released the drug and swell as they hydrated. These videos are buried in the supplementary files for the paper, but I thought it worthy of sharing more widely here:
In this collaborative paper—our second with the Malaysian team led by Dr Choon Fu Goh—we examine some commercially available cosmetic products and ask what lessons we can learn from them to enhance pharmaceutical microneedle product translation and commercialisation.
We have known, for a long time, that the regulatory hurdles for pharmaceutical products are much greater than those for cosmetic products. Still, it’s interesting to see how cosmetic microneedle products have surged years (if not decades) ahead of their pharmaceutical counterparts, particularly in the Asian market. A low regulatory hurdle could spur innovation, but it could equally grow fad. How can one tell which it is? We examined a selection of commercially available cosmetic microneedle products to find out, and report our findings in this paper.
This has been an interesting paper to work on. I have admired Goh’s tenacity collecting microneedle patches from pharmacies on his various international trips across Asia for this study. Last year, I hosted him in Newcastle to conduct parts of the study, including some microscopy work and the optical coherence tomography (OCT) analysis on microneedle penetration in ex vivo pig skin. It’s rewarding to see those efforts pay off.
We have been working with Professor Katarina Novakovic‘s team for several years now to develop long-acting microneedle patch formulations based on our ULTRA technology. ULTRA stands for Ultra-long and Tunable Release of Actives. It is a polymeric composite material that confers exceptional sustained release properties.
Our work in this area is yet unpublished, but it has already attracted the attention of RTS (Radio Television of Serbia), which featured the ULTRA microneedle technology in a segment of the documentary series, A Guide to the Future (Vodič kroz budućnost). The full-length documentary is available on YouTube and is mostly in Serbian (Wing and I speak about the ULTRA microneedle technology in English). The segment about our ULTRA microneedle technology starts around the 17-minute mark.
Thanks to RTS and their crew for their invaluable time and efforts in creating this fantastic coverage.
Hydrogels are a popular drug delivery vehicle. You can encapsulate drugs including large biological macromolecules like proteins in them, to be released in the body. Some hydrogels use chemical crosslinking to create the hydrogel matrix – with the drug in it. Can protein drugs encapsulated this way participate in those crosslinks? What if they do? How will that affect their subsequent release?
We started asking these questions when attempting to deliver protein drugs by encapsulating them in hydrogel-forming microneedle array patches. These were important questions, and now we have the answers.
In this paper, we address these questions using bovine serum albumin as a model drug, and a genipin-chitosan hydrogel as the drug delivery vehicle. Using a combination of empirical fluorometry data and mathematical modelling, we investigate the kinetics of the interactions of the protein drug and genipin (the crosslinker).
Our hands-free, ‘vac-and-fill’ micromoulding technique prevented air entrapment and bubble formation in viscous formulations when degassed under vacuum. Image from Smith E, et al. Int J Pharm 2024;650:123706. Licence: CC BY 4.0 Deed.
This paper reports the solution to a problem that took us several months to solve. We were trying to mould a microneedle array patch. There are basically two ways to do it: you fill the mould with the liquid formulation and either centrifuge it or degas it under vacuum. Both techniques are widely reported in the literature. They have been designed to force any air out of the microcavities in the mould, so that the formulation can enter them to form the microneedles. We didn’t have the right rotor to go with the centrifuge, so we opted for the vacuum degassing technique, fully expecting it to be a walk in the park. What a disappointment that turned out to be! We discovered that our formulation was too viscous to allow the air to escape. We ended up with a lot of air bubbles trapped in the liquid formulation.
We quickly realised that the vacuum degassing technique reported in the literature had used low polymer concentrations, which meant that their liquid formulations were not as viscous as ours. To micromould the microneedle array patch successfully from our viscous formulation, we had to remove the air first before filling the formulation into the mould. But how would one fill the mould under vacuum?
The answer: a modified syringe, a 3D-printed part, some painstaking calibration, and viola! The paper describes our solution in full, but here’s a peek of the contraption in action.
This is Emma’s first paper and our first together with Dr Katarina Novakovic‘s group. Congratulations, Emma, and thank you team for the hard work!
2023 seemingly left in a haste. Stepping into 2024, we welcomed our collaborators from The Hong Kong Polytechnic University (PolyU) to Newcastle, to conduct a joint study on microneedle formulation for drug delivery and diagnostics. Merab Naveed, Hubert Chan and Dr Thomas Lee from PolyU’s Biomedical Engineering Department spent nearly two weeks with us, running experiments and exchanging ideas with us. Newcastle University students, Begho Obale and Jakub Masloch, who completed their MPharm research projects with us, also lent their expertise to this joint study. Among other things, Begho made a dancing microneedle mould – the first ever reported. It was a most wonderful way to start the new year.
So how did our guests find it? I know Hubert enjoyed the unique learning experience – his words, not mine. I’m really pleased that we’re able to organise this research exchange programme. Thanks also go to Dr Wing Man Lau and Dr Hin Chung Lau of PolyU, the other two academic advisors on the project, for making this happen.